Pull to refresh
Logo
Daily Brief
Following Why Ranks Sign Up
Gene therapy options for Duchenne muscular dystrophy

Gene therapy options for Duchenne muscular dystrophy

New Capabilities

Regenxbio trial success sets up a second submission to the FDA

Today: Regenxbio gene therapy clears pivotal trial

Overview

For three years, Sarepta Therapeutics has been the only company in the world selling a gene therapy for Duchenne muscular dystrophy. Regenxbio's trial result on May 14, 2026, sets up a second contender for U.S. Food and Drug Administration (FDA) approval.

Why it matters

Roughly 12,000 American boys have Duchenne; a second gene therapy doubles their treatment options after safety questions emerged about the first.

Play on this story Voices Debate Predict

Key Indicators

10,000–15,000
U.S. patients with Duchenne
Almost all are boys; most are diagnosed before age 5.
$3.2M
Elevidys list price
Per-patient cost of Sarepta's one-time gene therapy, billed in a single dose.
2
Gene therapy contenders
Sarepta's approved Elevidys plus Regenxbio's pending FDA submission.
Mid-20s
Typical age of death
Without an effective treatment, Duchenne is fatal in early adulthood from heart and lung failure.

Interactive

Exploring all sides of a story is often best achieved with Play.

Ever wondered what historical figures would say about today's headlines?

Sign up to generate historical perspectives on this story.

Log in Sign Up

People Involved

Curran Simpson
Curran Simpson
Leading FDA submission for RGX-202
 Doug Ingram
Doug Ingram
Defending Elevidys against safety questions and new competition

Organizations Involved

Regenxbio
Regenxbio
Biotechnology company
Preparing FDA submission for RGX-202

Rockville, Maryland biotech that spun out of University of Pennsylvania gene therapy research and licenses its NAV adeno-associated virus (AAV) vector platform to other drugmakers.
Sarepta Therapeutics
Sarepta Therapeutics
Biotechnology company
Marketing Elevidys under restricted label

Cambridge, Massachusetts biotech that built its business around Duchenne treatments, including three exon-skipping drugs and the gene therapy Elevidys.
FDA Center for Biologics Evaluation and Research
FDA Center for Biologics Evaluation and Research
Federal regulatory agency division
Reviewing gene therapy approvals and safety

The U.S. Food and Drug Administration unit that reviews gene therapies, vaccines, and other biologic drugs.

Timeline

  1. Regenxbio gene therapy clears pivotal trial

    Clinical Trial

    Regenxbio announces RGX-202 met its primary endpoint in the pivotal AFFINITY DUCHENNE trial, clearing the way for an FDA submission.

  2. FDA's top gene therapy regulator resigns

    Personnel

    Peter Marks, the CBER director who approved Elevidys, resigns over policy disputes with the Department of Health and Human Services.

  3. Elevidys linked to patient deaths

    Safety

    Sarepta reports deaths from acute liver failure in non-ambulatory teens treated with Elevidys and voluntarily pauses dosing in that group.

  4. FDA expands Elevidys to all ages

    Regulatory

    FDA broadens the Elevidys label to cover ambulatory and non-ambulatory patients regardless of age, opening the drug to thousands more boys.

  5. Elevidys becomes first Duchenne gene therapy

    Regulatory

    FDA grants accelerated approval to Sarepta's Elevidys for ambulatory boys ages 4-5. List price: $3.2 million per one-time infusion.

  6. First Duchenne drug approved

    Regulatory

    FDA grants accelerated approval to Sarepta's Exondys 51, an exon-skipping drug, over the objections of agency reviewers who cited weak efficacy data.

  7. Dystrophin gene identified

    Science

    Researchers at Harvard pinpoint the gene that, when mutated, causes Duchenne. The discovery sets the target for every future Duchenne therapy.

Scenarios

Predict which scenario wins. Contrarian picks score more — points lock in when the scenario resolves.

Log in to predict. Track your picks, climb the leaderboard. Log in Sign Up
1

FDA approves Regenxbio's gene therapy

Regenxbio submits a biologics license application by late 2026, FDA grants priority review, and approval follows in 2027. The company launches at a list price near Elevidys and competes for new patients and switches. This is the base case given the pivotal trial success and FDA's willingness to approve Duchenne therapies on accelerated pathways.

Resolves by: 2027-12-31
Source: FDA Drugs@FDA database / FDA press release
Discussed by: STAT News, biotech analysts at Evercore ISI and Stifel
Consensus —
2

Safety signal emerges in Regenxbio follow-up

Adeno-associated virus gene therapies, including Elevidys and Zolgensma, have shown immune and liver toxicity. As Regenxbio dosed more patients and follow-up extended, a serious adverse event or death surfaces, forcing a trial pause or label restriction at submission. This would slow approval or narrow the eligible population.

Resolves by: 2027-06-30
Source: Regenxbio SEC filings and FDA safety communications
Discussed by: Duchenne family advocates, FDA gene therapy review staff
Consensus —
3

Sarepta's Elevidys label further restricted

With a viable second option in sight, FDA tightens Elevidys eligibility further, narrows the label to ambulatory boys only, or requires new safety studies. Sarepta could also withdraw the drug from non-ambulatory patients entirely. The agency has been more willing to act on safety since Peter Marks resigned in 2025.

Resolves by: 2027-05-14
Source: FDA-approved label on Drugs@FDA / Sarepta SEC filings
Discussed by: FDA reviewers, Sarepta investors, Duchenne patient organizations
Consensus —

Historical Context

Zolgensma approval for spinal muscular atrophy (2019)

May 2019

What Happened

FDA approved Novartis's Zolgensma, a one-time AAV gene therapy for spinal muscular atrophy in children under 2. At $2.1 million, it was the most expensive drug ever approved at the time. It used an AAV9 vector built on the Regenxbio NAV platform under license.

Outcome

Short Term

Zolgensma joined Biogen's earlier antisense drug Spinraza, giving SMA families two treatment options where they had none in 2015.

Long Term

Roche's Evrysdi followed in 2020, and SMA shifted from a near-certain infant fatality to a manageable condition for many patients.

Why It's Relevant Today

The same script may now play out for Duchenne. A second gene therapy arrives a few years after the first, giving doctors a choice and pressuring the incumbent on price and safety.

Hepatitis C drug competition (2014-2017)

December 2013 to 2017

What Happened

Gilead's Sovaldi launched in 2013 as a near-cure for hepatitis C, priced at $1,000 per pill or $84,000 per course. AbbVie's Viekira Pak launched the next year, followed by Gilead's own Harvoni and later Mavyret. Insurers and pharmacy benefit managers used the second entrant to negotiate steep rebates.

Outcome

Short Term

Net prices fell more than 50% within three years of the first competitor launch.

Long Term

Hepatitis C cure rates climbed past 95% in treated patients, and the U.S. cleared most of its diagnosed backlog by the early 2020s.

Why It's Relevant Today

Drug competition routinely lowers prices and broadens access. A second approved Duchenne gene therapy gives insurers and Medicaid programs leverage that did not exist with one supplier.

Elevidys accelerated approval debate (2023)

June 2023

What Happened

FDA's CBER division, then run by Peter Marks, approved Elevidys despite a divided advisory committee vote and objections from agency reviewers who said the efficacy data was thin. The approval was conditional, requiring a confirmatory trial.

Outcome

Short Term

Sarepta launched at $3.2 million per dose, the highest list price ever for an FDA-approved drug at the time of approval.

Long Term

When Elevidys was later linked to patient deaths, the original approval decision came under renewed scrutiny and contributed to Marks's resignation in March 2025.

Why It's Relevant Today

Regenxbio's submission lands in a more skeptical FDA. Reviewers will weigh safety more heavily than they did three years ago, and the bar for accelerated approval may be higher.

Sources

(1)
STAT News